Lilly (LLY.US) recommends Elpida peptide as a weight loss drug by the UK regulatory agency.

25/12/2024

The UK's National Institute for Health and Care Excellence has officially recommended the GLP-1 drug Tirzepatide from Lilly as a weight loss medication.

The UK's drug cost-effectiveness watchdog, the National Institute for Health and Care Excellence (NICE), has formally recommended Eli Lilly and Company's GLP-1 drug Tirzepatide as a weight loss medication. The drug is sold under the names Zepbound for weight loss and Moujaro for treating type 2 diabetes. Due to anticipated high demand, NICE had earlier stated in December that Tirzepatide would be rolled out over a three-year period, with the "highest clinical need" patients being given priority for the drug.

HK Stock Market Move | CANBRIDGE-B(01228) has risen by nearly 35%. The company is actively preparing for the negotiation of healthcare insurance in GeRuiNing and promoting the product's overseas market entry process.

ByteDance denies selling TikTok's US business to a US consortium led by Oracle Corporation (ORCL.US)

HK Stock Market Move | MEITUAN-W (03690) rose nearly 3% at the close, Meituan's preferred option ceased operations freeing up subsidy space, Nomura said Meituan could become the ultimate winner in the food delivery war.

ByteDance denies selling TikTok's US business to a US consortium led by Oracle Corporation (ORCL.US)